Contact Us!

Take a look at your situation and see how Fujitsu can help your organization.

Contact us now »

Fujitsu Drug Discovery Platform - Accelerate Innovation. Expand molecular space. Reduce time-to-hit.

 

Accelerate small molecule discovery with Fujitsu

Explore trillions of compounds in 3D to identify promising, synthesizable molecules faster.

 

Fujitsu’s Drug Discovery Platform helps medicinal and computational chemistry teams explore ultra-large chemical spaces, prioritise high-quality candidates, and support faster early-stage discovery decisions. 

Whether you are pursuing rare or challenging targets, looking to accelerate Design–Make–Test–Analyse cycles, or evaluating new approaches to small molecule discovery, Fujitsu offers both expert-led project services and QIMERA SaaS access to help you move from search to decision with confidence.

 

What slows down early-stage small molecule discovery?

Drug discovery is tough, but it doesn’t have to be slow, expensive, or limited by outdated tools. Are these things getting in the way?

 

 • 

Limited chemical space : Most Virtual Screening platforms screen millions. We screen trillions in 3D in hours.

 • 

DMTA drag: Long design–make–test–analyze loops slow everything down. Our platform accelerates Design and Make elements of your cycle.

 • 

Costly Dead ends: Progressed failures waste time and resources. We help you to find and discard non-developable materials early. Fail early. Fail Fast. Fail cheap.

 • 

Synthesizability risk: Generative AI models often suggest molecules you can’t even make. Our Platform harnesses ultra-large Make-on-Demand libraries (8 trillion + compounds) to guarantee synthetic feasibility of results. 

 • 

Complex tools and workflows: Powerful technology should not create extra burden for scientists.

 

What if you could explore trillions of synthetically tractable molecules in one sitting?

 

Two Ways to Power Up Your Pipeline with Fujitsu

Whether you want Fujitsu experts to run a tailored discovery project with you, or you want your scientists to access QIMERA directly through SaaS, Fujitsu offers flexible options for exploring chemical space, prioritising promising molecules and accelerating early-stage small molecule discovery.

Project Service

Project Service

A fully managed solution for teams that want expert support and deep customization.

Best suited for teams that want: 

  • Trillion-scale virtual libraries
  • Custom optimisation workflows using Fujitsu’s quantum-inspired capabilities
  • ADMEt prediction + physics-based screening
  • Expedited Make cycles with synthesis partners
  • Real-time iterative collaboration with Fujitsu drug discovery and CADD specialists
  • Workflows tailored to rare, challenging or poorly characterised target
  • Expert CADD consultancy to get the most out of your data
QIMERA SaaS

QIMERA SaaS

A secure SaaS platform for medicinal and computational chemistry teams that want direct access to Fujitsu’s small molecule discovery technology. 

Core SaaS capabilities include:

  • Bioisosteric replacement and molecular design workflows
  • An intuitive UI designed with the scientist in mind
  • No requirement for large training datasets
  • 3D shape and electrostatic searching
  • Rapid, iterative search and refinement in minutes
  • Secure AWS-based architecture
  • Accessible from anywhere, anytime
  • Live expert-led training and support documentation

Ultra

Ultra is a modular upgrade to QIMERA SaaS for teams that want to search ultra-large commercial make-on-demand libraries in 3D. It builds on QIMERA’s existing trillion-scale search capability by giving users access to commercially sourced compound spaces, helping them explore broader make-on-demand chemistry while keeping the workflow within the SaaS environment. 

With Ultra, SaaS users can:

  • Search ultra-large commercial make-on-demand libraries in 3D
  • Explore broader commercially available small molecule spaces
  • Prioritise compounds with clearer, more cost-effective routes to synthesis
  • Extend QIMERA SaaS workflows beyond standard chemical space search
  • Know the total cost of ownership: no unexpected compute costs

Compare the Options

 

Ready to Rethink Drug Discovery?

Don’t settle for slow Design cycles, limited libraries, or generic AI. Fujitsu’s Drug Discovery Platform empowers you to:

  • Process 3D molecular queries across trillions of compounds
  • Skip the need for pre-calculated libraries, GPUs, or expensive hardware
  • Achieve unmatched speed, precision, and cost-efficiency
  • Choose between a fully managed service or a fast, self-service SaaS

Your next breakthrough is just one query away.

QIMERA is being used in real-world small molecule drug discovery programmes by major pharmaceutical organisations, across both expert-led project collaborations and SaaS access.

Want to evaluate QIMERA for your own workflows? Contact us at drug-discovery@fujitsu.com or request a demo / 28-day trial licence using the booking link below.

Book a QIMERA demo